For the three months and full-year ended December 31, 2024, from continuing operations: Revenues of $697.0 million for the fourth quarter, $2,696.4 million for the full yearGAAP net loss of $(73.9) million for the fourth quarter, $(271.5) million for the full yearAdjusted EBITDA of $56.0 million for the fourth quarter, $202.5 million for the full yearFourth-quarter book-to-bill ratio of 1.35x DURHAM, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract r ...

Core Points - Fortrea sponsors the SCRS Collaborate Forward working group to enhance collaboration and improve clinical trial efficiency [1][2] - The working group consists of 16 leading Global Impact Partner organizations focused on reducing administrative burdens in clinical research [1][2] - The initiative aims to optimize internal processes, promote sustainability in clinical research institutions, and enhance patient experiences [1][2] Company Overview - Fortrea is a leading global provider of clinical development solutions in the life sciences sector, collaborating with biopharmaceutical, biotechnology, medical device, and diagnostic companies [5] - The company offers management services for Phase I to IV clinical trials, clinical pharmacology, and consulting services, leveraging over 30 years of experience across more than 20 therapeutic areas [5] - Fortrea operates in approximately 100 countries with a diverse team, providing targeted and flexible solutions to global clients [5] Industry Context - The clinical trial landscape is becoming increasingly complex, necessitating innovation to ensure patient safety and streamline processes [2] - The Collaborate Forward working group will focus initially on startup research, sharing success stories and data-driven insights to demonstrate the benefits of collaboration [2] - SCRS invites sponsors and CROs committed to sustainable research practices to contribute to a more efficient and collaborative clinical research environment [3]

Group 1 - Fortrea sponsors the SCRS Collaborate Forward working group to enhance collaboration and efficiency in clinical trials [1][3] - The working group consists of 16 Global Impact Partner organizations focused on reducing administrative burdens in clinical research [2] - The initiative aims to improve internal processes, making clinical research sites more sustainable and trials more efficient [2][4] Group 2 - Fortrea's involvement signifies a commitment to industry-wide innovation and prioritizing clinical research sites in trial planning [3][4] - The Collaborate Forward group will initially focus on study startup, sharing success stories and data-driven insights [4] - SCRS encourages other sponsors and CROs to join the effort for a more effective clinical research landscape [5] Group 3 - The Society for Clinical Research Sites (SCRS) represents over 11,000 research sites globally, advocating for site-focused initiatives [6] - Fortrea provides comprehensive clinical development solutions across various therapeutic areas, emphasizing its role in healthcare innovation [7][8]

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. regarding potential securities fraud or unlawful business practices [1] - Fortrea's stock has experienced significant declines following downgrades from Jefferies and Baird due to concerns over its business model and abrupt cancellations of scheduled conferences [2][3] Group 1: Company Performance - On September 25, 2024, Jefferies downgraded Fortrea, leading to a stock price drop of $2.73 per share, or 12.29%, closing at $19.48 per share [2] - On December 6, 2024, Baird downgraded Fortrea to neutral from outperform, resulting in a stock price decline of $1.90 per share, or 8.06%, closing at $21.67 per share [3] Group 2: Legal Investigation - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, and is currently investigating Fortrea for potential securities fraud [1][4]

Company Overview - Fortrea (Nasdaq: FTRE) is a leading global contract research organization (CRO) that provides clinical development solutions to the life sciences industry [3] - The company partners with biopharmaceutical, biotechnology, medical device, and diagnostic companies to accelerate healthcare innovation and deliver life-changing therapies to patients [3] - Fortrea offers services including phase I-IV clinical trial management, clinical pharmacology, and consulting, leveraging over 30 years of experience across more than 20 therapeutic areas [3] Financial Results Announcement - Fortrea will release its fourth quarter and full year 2024 financial results on March 3, 2025, before the market opens [1] - A conference call will be held at 9:00 am ET on the same day to review the financial results and conduct a Q&A session [1][2] Participation Details - Participants can register for the earnings call online at the Fortrea Investor Relations website and are advised to join at least 10 minutes early to avoid delays [2] - A replay of the conference call will be available shortly after the event on the Fortrea Investor Relations website [2]

Group 1 - The article highlights that while investors are focused on tech stocks in 2024, the healthcare sector is also experiencing significant innovation [1] - There is a suggestion that the healthcare industry may offer comparable investment opportunities as the tech sector, despite being overlooked [1] Group 2 - The author has a beneficial long position in the shares of FRTE, indicating a personal investment interest in the stock [1] - The article emphasizes the author's experience and success in the stock market, with an average stock return of over 31% from previous articles [2]

DURHAM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and Chief Financial Officer, Jill McConnell will present at the Citi Global Healthcare Conference on Wednesday, December 4, 2024 at 1:45 pm ET. The live webcast will be available to investors and other interested parties by accessing the Fortrea Investor Relations website. A webcast replay will be available after th ...

DURHAM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and Chief Financial Officer, Jill McConnell will present at the Evercore HealthCONx Conference on Thursday, December 5, 2024 at 10:00 am ET. The live webcast will be available to investors and other interested parties by accessing the Fortrea Investor Relations website. A webcast replay will be available after the e ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number 001-41704 FORTREA HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 92-2796441 | --- | --- | --- ...

Fortrea Holdings, Inc. (NASDAQ:FTRE) Q3 2024 Earnings Conference Call November 8, 2024 8:00 AM ET Company Participants Hima Inguva - Head, IR & Corporate Development Tom Pike - CEO Jill McConnell - CFO Conference Call Participants Eric Coldwell - Baird Patrick Donnelly - Citi Justin Bowers - DB Luke Sergott - Barclays David Windley - Jefferies Elizabeth Anderson - Evercore Max Smock - William Blair Will Ortmayer - Goldman Sachs John Kim - Bank of America Operator Ladies and gentlemen, thank you for standing ...